Pacific Biosciences of California Inc（PACB）價格預測PACBPacific Biosciences of California Inc

Alphio's PACB stock price prediction model matches the current Pacific Biosciences of California Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.40 (+0.25%). The 1-week path is $1.27 (-9.00%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Pacific Biosciences (PACB) is currently not a strong buy due to its recent performance and outlook. The stock is priced at $1.40, which is below the analyst target of $1.50, indicating limited upside potential. Additionally, the company reported a significant year-to-date decline of 23.91% and has a negative forward P/E ratio of 0, reflecting uncertainty in future earnings. The recent resignation of the CEO and a downgraded revenue outlook for 2026 to $155-$165 million further complicate the investment case. The main risk lies in the company's high debt-to-equity ratio of 27223.46%, which poses a financial stability concern. Overall, while there are some positive indicators, such as a recent 5-day price increase of 3.70%, the overall sentiment and financial metrics suggest holding rather than buying at this time.

Pacific Biosciences of California Inc (PACB) last closed at $1.4, losing -9.68%. These facts feed the 1-day and 1-week PACB price prediction above.